PDF herunterladen
Pharmacopsychiatry 2015; 48(01): 19-24
DOI: 10.1055/s-0034-1394398
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases

M. Gahr
1   Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
,
R. Zeiss
1   Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
,
D. Lang
2   Department of Psychosomatic Medicine and Psychotherapy, University of Ulm, Ulm, Germany
,
B. J. Connemann
1   Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
,
C. Hiemke
3   Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany
,
R. W. Freudenmann
1   Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
,
C. Schönfeldt-Lecuona
1   Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 03. Juli 2014
revised 11. September 2014

accepted 30. September 2014

Publikationsdatum:
06. November 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Erratum zu diesem Artikel:

Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance DatabasesPharmacopsychiatry 2015; 48(01): e1-e1
DOI: 10.1055/s-0032-1395594

Abstract

Introduction: There is increasing evidence for an association between treatment with selective serotonin reuptake inhibitors (SSRI) and an increased risk of bleeding events. The most important underlying mechanism appears to be inhibition of serotonin uptake in platelets, an effect that is also present in antidepressants with non-selective serotonin-reuptake inhibition (NSRI). Accordingly, also NSRI may be associated with an increased risk of bleeding. However, there is little data in this regard.

Methods: Based on data (spontaneous reports of adverse drug reactions) from 2 pharmacovigilance databases (WHO-database/VigibaseTM; BfArM/AkdÄ-database in Germany) we used a case/non-case approach and calculated reporting odds ratios (ROR) as measures for disproportionality regarding the association of treatment with an agent of the group SSRI/NSRI and haemorrhages.

Results: Whereas both positive control agents (ASS and diclofenac) were statistically associated with haemorrhages in both databases (ASS: BfArM/AkdÄ, ROR 13.62 [95% CI 12.76−14.53]/WHO, ROR 12.96 [95% CI 12.75−13.16]; diclofenac: BfArM/AkdÄ, ROR 3.01 [95% CI 2.71−3.21]/WHO, ROR 2.11 [95% CI 2.05−2.16]), none of the agents of the group SSRI (ROR<1) was associated with haemorrhages. In group NSRI, only St. John’s wort/hypericum was associated with haemorrhages (WHO-database, ROR 1.31 [95% CI 1.06−1.63]).

Discussion: Signal detectioning in 2 pharmacovigilance databases suggest that serotonin reuptake inhibition is not associated with an increased risk of bleeding. However, underreporting may have accounted for the evaluated absent associations, particularly concerning SSRI. Regarding the detected increased risk of bleeding associated with hypericum, pharmacokinetic drug-drug interactions may be relevant independent of serotonin reuptake inhibition.

Key words

haemorrhages - pharmacokinetics - signal detection - WHO
 

  • References

  • 1 Mulrow C, Williams JJ, Chiquette E et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000; 108: 54-64
    CrossrefPubMedGoogle Scholar
  • 2 Sonnenberg C, Deeg D, Comijs H et al. Trends in antidepressant use in older populations: results from the LASA-study over a period of 10 years. J Affect Disord 2008; 111: 299-305
    CrossrefPubMedGoogle Scholar
  • 3 Lockhart P, Guthrie B. Trend in primary care antidepressant prescribing 1995–2007: a longitudinal population based analysis. Br J Gen Pract 2011; 61: e565-e572
    CrossrefPubMedGoogle Scholar
  • 4 Hemels M, Koren G, Einarson T. Increased use of antidepressants in Canada: 1981–2000. Ann Pharmacother 2002; 36: 1375-1379
    CrossrefPubMedGoogle Scholar
  • 5 Percudani M, Barbui C, Fortino I et al. Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord 2004; 83: 169-175
    CrossrefPubMedGoogle Scholar
  • 6 Wijlaars L, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One 2012; 7: e33181
    CrossrefPubMedGoogle Scholar
  • 7 Skaer T, Sclar D, Robison L. Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. Clin Ther 2009; 31 (Pt 1) 1478-1487
    CrossrefPubMedGoogle Scholar
  • 8 Buckley N, McManus P. Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325: 1332-1333
    CrossrefPubMedGoogle Scholar
  • 9 MacGillivray S, Arroll B, Hatcher S et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003; 326: 1014
    CrossrefPubMedGoogle Scholar
  • 10 Goldstein B, Goodnick P. Selective serotonin reuptake inhibitors in the treatment of affective disorders – II. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998; 12: S55-S87
    CrossrefPubMedGoogle Scholar
  • 11 Vaswani M, Linda F, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 85-102
    CrossrefPubMedGoogle Scholar
  • 12 Calhoun J, Calhoun D. Prolonged bleeding time in a patient treated with sertraline. Am J Psychiatry 1996; 153: 443
    PubMedGoogle Scholar
  • 13 Lake M, Birmaher B, Wassick S et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10: 35-38
    CrossrefPubMedGoogle Scholar
  • 14 Pai V, Kelly M. Bruising associated with the use of fluoxetine. Ann Pharmacother 1996; 30: 786-788
    PubMedGoogle Scholar
  • 15 Aranth J, Lindberg C. Bleeding, a side effect of fluoxetine. Am J Psychiatry 1992; 149: 412
    PubMedGoogle Scholar
  • 16 Ottervanger J, Stricker B, Huls J et al. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994; 151: 781-782
    CrossrefPubMedGoogle Scholar
  • 17 Andersohn F, Konzen C, Bronder E et al. Citalopram-induced bleeding due to severe thrombocytopenia. Psychosomatics 2009; 50: 297-298
    CrossrefPubMedGoogle Scholar
  • 18 Holzer L, Halfon O. Setraline and gastrointestinal bleeding in an adolescent girl. J Child Adolesc Psychopharmacol 2006; 16: 1-2
    CrossrefPubMedGoogle Scholar
  • 19 Andrade C, Sandarsh S, Chethan K et al. Serotonin reuptake inhibitors antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565-1575
    CrossrefPubMedGoogle Scholar
  • 20 Labos C, Dasgupta K, Nedjar H et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183: 1835-1843
    CrossrefPubMedGoogle Scholar
  • 21 Cochran K, Cavallari L, Shapiro N et al. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit 2011; 33: 433-438
    CrossrefPubMedGoogle Scholar
  • 22 Schalekamp T, Klungel O, Souverein P et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168: 180-185
    CrossrefPubMedGoogle Scholar
  • 23 de Abajo F, Garcia-Rodriguez L. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interactions with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803
    CrossrefPubMedGoogle Scholar
  • 24 de Abajo F, Rodriguez L, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-1109
    PubMedGoogle Scholar
  • 25 Dalton S, Johansen C, Mellemkjaer L et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64
    CrossrefPubMedGoogle Scholar
  • 26 Targownik L, Bolton J, Metge C et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475-1482
    CrossrefPubMedGoogle Scholar
  • 27 Wang Y, Chen Y, Tsai C et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointenstinal bleeding. Am J Psychiatry 2014; 171: 54-61
    CrossrefPubMedGoogle Scholar
  • 28 Mortensen J, Larsson H, Johnsen S et al. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke 2013; 44: 420-426
    CrossrefPubMedGoogle Scholar
  • 29 Auerbach A, Vittinghoff E, Maselli J et al. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes in surgery. JAMA Intern Med 2013; 173: 1075-1081
    CrossrefPubMedGoogle Scholar
  • 30 Shin D, Oh Y, Eom C et al. Use of selective serotonin reuptake inhibitors as risk of stroke: a systematic review and meta-analysis. J Neurol 2014; 261: 686-695
    CrossrefPubMedGoogle Scholar
  • 31 Hackam D, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79: 1862-1865
    CrossrefPubMedGoogle Scholar
  • 32 Serebruany V. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?. Am J Med 2006; 119: 113-116
    CrossrefPubMedGoogle Scholar
  • 33 Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9: 47-59
    PubMedGoogle Scholar
  • 34 Abdel Salam O. Fluoxetine and sertraline stimulate gastric acid secretion via a vagal pathway in anaesthetised rats. Pharmacol Res 2004; 50: 309-316
    CrossrefPubMedGoogle Scholar
  • 35 Yamaguchi T, Hidaka N, Suemaru K et al. The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats. Biol Pharm Bull 2008; 31: 1371-1375
    CrossrefPubMedGoogle Scholar
  • 36 de Jong J, van den Berg P, Tobi H et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003; 55: 591-595
    CrossrefPubMedGoogle Scholar
  • 37 Zullino D, Khazaal Y. Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions. Br J Clin Pharmacol 2005; 59: 118-119
    CrossrefPubMedGoogle Scholar
  • 38 Pedrazza E, Senger M, Rico E et al. Fluoxetine and nortriptyline affect NTPDase and 5′-nucleotidase activities in rat blood serum. Life Sci 2007; 81: 1205-1210
    CrossrefPubMedGoogle Scholar
  • 39 Schelleman H, Brensinger C, Bilker W et al. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One 2011; 6: e21447
    CrossrefPubMedGoogle Scholar
  • 40 Hampel H, Berger C, Kuss H et al. Unstable anticoagulation in the course of amitriptyline treatment. Pharmacopsychiatry 1996; 29: 33-37
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Perahia D, Bangs M, Zhang Q et al. The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug Healthc Patient Saf 2013; 5: 211-219
    PubMedGoogle Scholar
  • 42 Balhara Y, Sagar R, Varghese S. Bleeding gums: duloxetine may be the cause. J Postgrad Med 2007; 53: 44-45
    CrossrefPubMedGoogle Scholar
  • 43 Gross C, Klocker M, Jakob T et al. Dermatological side effects during therapy with serotonin noradrenaline reuptake inhibitors. Nervenarzt 2008; 79 (1304) 1307-1309
    PubMedGoogle Scholar
  • 44 Chappell J, He J, Knadler M et al. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. J Clin Pharmacol 2009; 49: 1456-1466
    CrossrefPubMedGoogle Scholar
  • 45 Rubell E. Does imipramine (Tofranil) cause oral bleeding?. Pediatrics 1969; 43: 144-145
    PubMedGoogle Scholar
  • 46 König F, Stumpp W, Wolfersdorf M et al. Follow-up of Werlhof disease after onset of treatment with maprotiline. Nervenarzt 1995; 66: 60-65
    PubMedGoogle Scholar
  • 47 Crampsey D, Douglas C, Cooke L. Nasal insertion of St John’s wort: an unusual cause of epistaxis. J Laryngol Otol 2007; 121: 279-280
    PubMedGoogle Scholar
  • 48 Yavasoglu I, Kadikoylu G, Bolaman Z. Gingival bleeding due to venlafaxine. Ann Pharmacother 2008; 42: 144-145
    PubMedGoogle Scholar
  • 49 Ghio L, Puppo S, Presta A. Venlafaxine and risk of upper gastrointestinal bleeding in elderly depression. Curr Drug Saf 2012; 7: 389-390
    CrossrefPubMedGoogle Scholar
  • 50 Linnebur S, Saseen J, Pace W. Venlafaxine-associated vaginal bleeding. Pharmacotherapy 2002; 22: 652-655
    CrossrefPubMedGoogle Scholar
  • 51 Benazzi F. Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression. Can J Psychiatry 2005; 50: 184
    PubMedGoogle Scholar
  • 52 de Abajo F, Garcia-Rodriguez L. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803
    CrossrefPubMedGoogle Scholar
  • 53 Opatrny L, Delaney J, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81
    CrossrefPubMedGoogle Scholar
  • 54 van Manen R, Fram D, DuMouchel W. Signal detection methodologies to support effective safety management. Expert Opin Drug Saf 2007; 6: 451-464
    CrossrefPubMedGoogle Scholar
  • 55 Gould A. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003; 12: 559-574
    CrossrefPubMedGoogle Scholar
  • 56 Ooba N, Kubota K. Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiol Drug Saf 2010; 19: 1159-1165
    CrossrefPubMedGoogle Scholar
  • 57 Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18: 427-436
    CrossrefPubMedGoogle Scholar
  • 58 Finney D. Statistical logic in the monitoring of reactions to therapeutic drugs. Methods Inf Med 1971; 10: 237-245
    PubMedGoogle Scholar
  • 59 van Puijenbroek E, Bate A, Leufkens H et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10
    CrossrefPubMedGoogle Scholar
  • 60 Rothman K, Lanes S, Sacks S. The reporting odds ratio and its advantages over the proportional reporting odds ratio. Drug Saf 2004; 13: 519-523
    PubMedGoogle Scholar
  • 61 Evans S. Pharmacovigilance: a science or fielding emergencies?. Stat Med 2000; 19: 3199-3209
    CrossrefPubMedGoogle Scholar
  • 62 Williams D, Feely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci 1999; 168: 257-261
    CrossrefPubMedGoogle Scholar
  • 63 Begaud B, Martin K, Haramburu F et al. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288: 1588
    CrossrefPubMedGoogle Scholar
  • 64 Berthold H, Schott G, Muller-Oerlinghausen B. Pharmakovigilanz: Empfehlungen zur Meldung unerwünschter Arzneimittelwirkungen durch die Ärzteschaft. Arzneiverordnung in der Praxis 2005; 32: 1-31
    PubMedGoogle Scholar
  • 65 Martin R, Kapoor K, Wilton L et al. Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study. BMJ 1998; 317: 119-120
    CrossrefPubMedGoogle Scholar
  • 66 Anglin R, Yuan Y, Moayyedi P et al. Risk of upper gastrointestinal bleeding with selective serotononin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review a metaanalysis. Am J Gastroenterol 2014; 109: 811-819
    CrossrefPubMedGoogle Scholar
  • 67 Wahab AI, Pratt N, Kalisch E et al. Comparing time to adverse drug reaction signals in a spontaneus reporting database and a claims database a case study of rofecoxib-indiced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug Saf 2014; 37: 53-64
    CrossrefPubMedGoogle Scholar
  • 68 Rahimi R, Abdollahi M. An update on the ability of St. John’s wort to affect the metabolism of other drugs. Expert Opin Drug Metabol Toxicol 2012; 8: 691-708
    CrossrefPubMedGoogle Scholar
  • 69 Caraci F, Crupi R, Drago F et al. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011; 12: 570-577
    CrossrefPubMedGoogle Scholar
  • 70 Izzo A, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69: 1777-1798
    CrossrefPubMedGoogle Scholar
  • 71 Di Y, Li C, Xue C et al. Clinical drugs that interact with St. John’s wort and implication in drug development. Curr Pharm Des 2008; 14: 1723-1742
    CrossrefPubMedGoogle Scholar
  • 72 de Abajo F. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011; 28: 345-367
    CrossrefPubMedGoogle Scholar